Critical role for Epac1 in inflammatory pain controlled by GRK2-mediated phosphorylation of Epac1

Pooja Singhmar\(^a,1\), XiaoJiao Huo\(^a\), Niels Eijkelkamp\(^b\), Susana Rojo Berciano\(^c,d\), Faiza Baameur\(^a\), Fang C. Mei\(^a\), Yingmin Zhu\(^a\), Xiaodong Cheng\(^a\), David Hawke\(^a\), Federico Mayor Jr.\(^c,d\), Cristina Murga\(^c,d\), Cobi J. Heijnen\(^a\), and Annemieke Kavelaars\(^a,1\)

\(^a\)Laboratory of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030; \(^b\)Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, The Netherlands; \(^c\)Departamento de Biologia Molecular y Centro de Biologia Molecular Severo Ochoa, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, Madrid 28049, Spain; \(^d\)Instituto de Investigación Sanitaria La Princesa, Madrid 28049, Spain; \(^e\)Department of Integrative Biology and Pharmacology and Texas Therapeutics Institute, University of Texas Health Science Center, Houston, TX 77030; and \(^f\)Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030

Edited by Robert J. Lefkowitz, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC, and approved February 2, 2016 (received for review August 12, 2015)

Significance

Chronic pain represents a massive therapeutic challenge that requires understanding of underlying mechanisms to develop novel treatments. We show that genetic deletion of the Rap1 guanine-nucleotide exchange factor Epac1 protects against chronic inflammatory mechanical hyperalgesia. Moreover, an orally active Epac inhibitor reverses existing inflammatory pain without affecting normal pain sensitivity. Epac1-mediated pain is controlled by G protein kinase 2 (GRK2) through inhibition of Epac1-to-Rap1 signaling and inhibition of sensitization of mechanocurrents mediated by Piezo2. Molecularly, GRK2 controls Epac1-to-Rap1 signaling by phosphorylating Epac1 at Ser-108 to inhibit plasma membrane accumulation of Epac1. Our findings provide further insights into the molecular pathways regulating Epac1 activity, demonstrate its key role in chronic pain, and identify Epac1 as a potential target for treatment of chronic pain.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

\(^1\)To whom correspondence should be addressed. Email: akavelaars@mdanderson.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1516036113/-/DCSupplemental.

Today >116 million adults in the United States are affected by chronic pain (1), which is accompanied by disability, depression, and reduced quality of life. Chronic pain is associated with multiple inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, and posturgical inflammation (1). Inflammatory mediators (including PGE2, substance P, bradykinin, ATP, and IL-1β) act on primary sensory neurons (nociceptors) and alter the excitability of nociceptors via transcriptional and/or posttranslational mechanisms to cause pain hypersensitivity (hyperalgesia). cAMP signaling plays a key role in pain signaling, and mice deficient in adenylate cyclase activity are protected against development of chronic neuropathic pain (7), but it is not known whether Epac1 is also required for inflammatory pain.

Epac1 is a guanine nucleotide exchange factor (GEF) catalyzing the exchange of GDP for GTP for the Ras-like GTPases Rap1 and Rap2, resulting in their activation (8–10). Subcellular localization of Epac1 is dynamic and spatiotemporally regulated. In cells, agonist stimulation induces rapid translocation of cytosolic Epac1 to the plasma membrane (PM), where it binds phosphatidic acid (PA) via its Disheveled/Egl-10/pleckstrin domain (DEP) domain and activates a local Rap1 pool (11, 12). In vitro it has been shown that activated Rap signals to, e.g., Akt (13), PLC-ε (14), PKC, and MAPKs (15). Our recently published work showed that the serine–threonine kinase G protein-coupled receptor kinase 2 (GRK2) inhibits Epac1-mediated pain signaling (16, 17). Specifically, we showed that chronic inflammatory pain is associated with a decrease in GRK2 levels in pain-sensing neurons and that either increasing GRK2 protein levels or reducing Epac1 levels prevents chronic pain (17). However, the mechanism via which GRK2 controls Epac1-mediated pain signaling remained to be identified. Here we demonstrate that Epac1 is required for inflammation-induced mechanical hyperalgesia.

cAMP signaling plays a key role in regulating pain sensitivity. Here, we uncover a previously unidentified molecular mechanism in which direct phosphorylation of the exchange protein directly activated by cAMP 1 (Epac1) by G protein kinase 2 (GRK2) suppresses Epac1-to-Rap1 signaling, thereby inhibiting persistent inflammatory pain. Epac1−/− mice are protected against inflammatory hyperalgesia in the complete Freund’s adjuvant (CFA) model. Moreover, the Epac-specific inhibitor ESI-09 inhibits established CFA-induced mechanical hyperalgesia without affecting normal mechanical sensitivity. At the mechanistic level, CFA increased activity of the Epac target Rap1 in dorsal root ganglia of WT, but not of Epac1−/−, mice. Using sensory neuron-specific overexpression of GRK2 or its kinase-dead mutant in vivo, we demonstrate that GRK2 inhibits CFA-induced hyperalgesia in a kinase activity-dependent manner. In vitro, GRK2 inhibits Epac1-to-Rap1 signaling by phosphorylation of Epac1 at Ser-108 in the Disheveled/Egl-10/pleckstrin domain. This phosphorylation event inhibits agonist-induced translocation of Epac1 to the plasma membrane, thereby reducing Rap1 activation. Finally, we show that GRK2 inhibits Epac1-mediated sensitization of the mechanosensor Piezo2 and that Piezo2 contributes to inflammatory mechanical hyperalgesia. Collectively, these findings identify a key role of Epac1 in chronic inflammatory pain and a molecular mechanism for controlling Epac1 activity and chronic pain through phosphorylation of Epac1 at Ser-108. Importantly, using the Epac inhibitor ESI-09, we validate Epac1 as a potential therapeutic target for chronic pain.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

To whom correspondence should be addressed. Email: akavelaars@mdanderson.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1516036113/-/DCSupplemental.
show that Epac1-dependent mechanical hyperalgesia is associated with increased activation of its target Rap1 in dorsal root ganglia (DRG). Moreover, we unveil a previously unidentified molecular mechanism for controlling Epac1 activity and chronic pain through GRK2-mediated phosphorylation of Ser-108 in Epac1, leading to inhibition of Epac1-to-Rap1 signaling. GRK2 also inhibits Epac1-mediated sensitization of the mechanosensitive channel Piezo2, and in vivo, reducing Piezo2 inhibits inflammatory mechanical hyperalgesia. Moreover, we demonstrate that the Epac inhibitor ESI-09 treats chronic inflammatory pain.

Results

Complete Freund’s Adjuvant-Induced Mechanical Hyperalgesia Is Dependent on Epac1 and Is Associated with Rap1 Activation. We first assessed the role of Epac1 in inflammatory hyperalgesia. We show that Epac1−/− mice are fully protected against development of complete Freund’s adjuvant (CFA)-induced mechanical hyperalgesia (Fig. 1A). CFA-induced thermal hyperalgesia and baseline mechanical and thermal sensitivity were not affected by genetic deletion of Epac1 (Fig. S1) (7).

Underlining the key role of Epac1 in persistent inflammatory mechanical hyperalgesia, the competitive Epac-inhibitor ESI-09 dose-dependently inhibited already-established mechanical hyperalgesia in a dose- and time-dependent manner (Fig. 1B) without affecting mechanical sensitivity of control mice (Fig. S2). In line with our data in Epac1−/− mice, ESI-09 did not affect CFA-induced heat hyperalgesia (Fig. S2) or baseline heat sensitivity (Fig. S2). ESI-09 also did not influence CFA-induced paw edema or granulocyte infiltration (Fig. S3).

Epac1 is a GEF for the small GTPase Rap1. The results in Fig. 1 show that in vivo CFA increases Rap1–GTP levels in the DRG of WT mice, but not in Epac1−/− mice (Fig. 1C). Collectively, these findings indicate that Epac1 is required for CFA-induced inflammatory hyperalgesia and that the Epac1-to-Rap1 signaling pathway is operative in nociceptors.

GRK2 Kinase Activity Inhibits Epac1-Dependent Inflammatory Hyperalgesia and Epac1 Signaling to Rap1. To determine whether GRK2 regulates Epac1-dependent inflammatory mechanical hyperalgesia in a kinase-activity dependent manner, we used herpes simplex virus (HSV) amplicons to overexpress GRK2 or the kinase-dead mutant GRK2–K220R. Intraplantar injection of HSV–GRK2 reduced CFA-induced hyperalgesia, demonstrating that GRK2 regulates Epac1-dependent inflammatory mechanical hyperalgesia (Fig. 2A). Injection of HSV–GRK2–K220R did not have any effect on the mechanical hyperalgesia, indicating the requirement of GRK2 kinase-activity for inhibiting inflammatory pain. Both constructs induced a similar increase in GRK2 levels in DRG neurons (Fig. S4).

Next, we assessed whether GRK2 kinase activity inhibits Rap1 activation in response to the Epac1 agonist 8-pCPT using a Rap1–GTP pull-down assay with the human Ral GDS–Rap binding domain (18). GRK2 overexpression in HEK cells or in the neuronal cell line Neuro2a (N2A) inhibited Epac1-to-Rap1 signaling (Fig. 2B and C), whereas overexpression of the kinase-dead mutant GRK2–K220R did not affect Epac1-to-Rap1 signaling (Fig. 2D).

GRK2 Phosphorylates Epac1 at Residue Ser-108 to Inhibit Rap1 Activation. Using pull-down analysis and live cell imaging, we show that in cells, GRK2 and Epac1 are part of the same protein complex and the interaction is mediated by the kinase domain of GRK2 (Fig. S5). Moreover, PM tethering of GRK2 using mcherry-tagged geranyl-geranyl-GRK2 (GRK2gg) recruited YFP-Epac1 to the PM (Fig. S5).

An in vitro kinase assay with GRK2 and GST–Epac1 protein showed that GRK2 phosphorylates Epac1 with a $K_m$ of ~77 nM (Fig. 3A and B; Fig. S6). Phosphorylation of Epac1 was abolished in the presence of heparin, a known inhibitor of GRK2 kinase activity that is frequently used in vitro for this purpose (19, 20) (Fig. 3A).

Mass spectrometry analysis of Epac1 phosphorylated

Fig. 1. Role of Epac1 in mechanical hyperalgesia. (A) CFA-induced mechanical hyperalgesia in WT ($n = 6$) and Epac1−/− ($n = 10$) mice. Changes in 50% paw withdrawal threshold were monitored over time. Repeated-measures two-way ANOVA genotype effect; $P < 0.0001$. **$P < 0.01$ (post hoc Bonferroni analysis). (B) Dose–response curve for the effect of ESI-09 (5, 20, or 50 mg/kg) on CFA-induced mechanical hyperalgesia in WT mice ($n = 8$). Treatment was started on the third day after CFA administration. *$P < 0.05$; **$P < 0.01$ (50 mg/kg ESI-09 compared with the vehicle-treated mice); ***$P < 0.001$; ****$P < 0.0001$; ***$P < 0.01$ (20 mg/kg ESI-09 compared with the vehicle-treated mice); ****$P < 0.0001$. (C) Rap1 activation in lumbar DRG of WT and Epac1−/− mice 5 d after CFA administration. Results are means ± SEM of at least three independent experiments. *$P < 0.05$ (t test); ns, not significant.
GRK2-mediated regulation of Epac1-to-Rap1 signaling and chronic pain. (A) Effect of overexpression of kinase dead GRK2 (K220R) on mechanical hyperalgesia (n = 8 per group). Mice were treated intraplantarly with HSV-GFP (empty vector) or HSV-K220R on days 4, 6, 13, and 16 after intraplantar CFA injection. Changes in 50% paw withdrawal threshold were monitored over time. Data represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data were analyzed by using two-way ANOVA followed by Tukey’s post hoc analyses. (B) Rap1 activation in HEK293 (HEK) or HEK293 cells overexpressing GRK2 (HEK-GRK2) cells. Cells transfected with HA-Epac1 were treated with 8-pCPT or vehicle for 20 min followed by a Rap1-GTP pull-down assay. Bar graph depicts means ± SEM of at least three independent experiments. **P < 0.01; ***P < 0.001; ****P < 0.0001 (analyzed using t test). (C) Pull-down of Rap1-GTP from N2A cells or N2A overexpressing GRK2 (N2A-GRK2). The two right lanes represent two different GRK2-overexpressing clones. (D) Rap1 activation in N2A-GRK2 or –K220R cells transfected with HA-Epac1. Cells were stimulated as in B. Data are representative of at least three independent experiments. Bars represent band density for Rap1-GTP levels normalized to total Rap1, with Rap1-GTP levels in 8-pCPT-treated control N2A cells set as 1. ***P < 0.001; ****P < 0.0001.

Phosphorylation of Epac1 at Ser-108 Inhibits Rap1 Activation by Inhibiting PM Association. Based on NMR studies of Epac1 and X-ray crystallographic studies of Epac2, it has been suggested that binding of cAMP or 8-pCPT induces an open conformation of Epac1, allowing the CDC25-HD domain to exert GEF activity toward Rap1 (8, 21–23). An intramolecular Epac1 FRET probe (24) stimulated with 8-pCPT induced a similar decrease in fluorescence energy transfer in cells expressing WT-Epac1 as in cells expressing the phosphory-mimic mutant of Epac1 (Fig. 4A). These data indicate that phosphorylation of Ser-108 does not impair the 8-pCPT-induced conformational dynamics of Epac1 or its capacity to activate Rap1 in vitro.

An in vitro fluorescence-based GEF assay with purified Rap1 showed that WT, phospho-mimic, and phospho-deficient Epac1 have a similar capability to catalyze the GDP to GTP exchange on Rap1 (Fig. 4B). Moreover, addition of GRK2 and ATP as a phosphate donor did not affect the agonist-induced GEF activity of WT GST–Epac1 (Fig. 4C).

In cells, 8-pCPT stimulation induces translocation of cytosolic Epac1 to the PM, where it activates a local Rap1 pool. The results in Fig. 5A demonstrate that 8-pCPT–induced translocation of the phospho-mimic mutant of Epac1 (Epac1–S108E) was significantly reduced compared with WT Epac1. Conversely, siRNA-mediated knockdown of GRK2 increased the 8-pCPT–induced PM translocation of WT Epac1 (Fig. 5B; Fig. 8S). Moreover, tethering the phospho-mimic mutant of Epac1 to the PM by adding a CAAX-motif (ICUE1–PM–S108E) restored 8-pCPT–induced Rap1 activation (Fig. 5C), supporting the model that phosphorylation of Epac1 by GRK2 at Ser-108 inhibits Epac1-to-Rap1 signaling by preventing its binding to the PM.
GRK2 cells expressing Piezo2 and Epac1. GTP levels were increased in μmice. Thus, although multiple signaling pathways can be activated, Rap1 is required for Rap1 activation in the DRG in the context of inflammatory pain.

Earlier studies by us and others have shown that Epac1 protein levels in the DRG are increased in the CFA model of chronic inflammatory pain, whereas GRK2 levels are decreased (16, 17, 30–32). In addition, we presented evidence that Epac1-dependent pain signaling is inhibited by GRK2, but the mechanism remained to be determined (17). Here, we identify GRK2, to our knowledge, as the first kinase known to directly phosphorylate Epac1, identify the site of phosphorylation, and demonstrate that this phosphorylation event inhibits Epac1-to-Rap1 signaling. We also demonstrate that, in vivo, GRK2 kinase activity is required for inhibition of Epac1-dependent inflammatory mechanical hyperalgesia. These findings suggest a potential role of Epac1 in the control of pain signaling.

Discussion

We demonstrate here that Epac1 is required for inflammatory mechanical hyperalgesia and describe a previously unidentified mechanism for controlling Epac1 signaling that inhibits inflammatory pain in vivo. Specifically, we demonstrate that Rap1 is activated in the DRG of mice with CFA-induced inflammatory pain, but not in Epac1−/− mice that are protected from mechanical hyperalgesia. At the molecular level, we demonstrate that phosphorylation of Ser-108 in Epac1 by the kinase GRK2 inhibits Epac1-to-Rap1 signaling via preventing agonist-induced accumulation of Epac1 at the PM. We propose that this molecular mechanism underlies the protective effect of GRK2 on chronic inflammatory pain.

The competitive Epac inhibitor ESI-09 (25, 26) inhibits mechanical hyperalgesia in the CFA model of inflammatory pain, and preliminary data indicate that the same is true for the spared nerve injury model of chronic neuropathic pain. Conversely, intraplantar administration of the Epac agonist 8-pCPT induces mechanical hyperalgesia (6, 7, 16, 27). In vitro, ESI-09 inhibits both Epac1 and Epac2 (27, 28), and there is evidence that both Epac1 (7) and Epac2 (29) contribute to sensitization of pain-sensing neurons. We demonstrate here that Epac1−/− mice are protected from mechanical hyperalgesia in the CFA model of inflammatory pain and that these mice are also protected against neuropathic pain (7). Therefore, we propose that Epac1 is the main target for the pain-relieving effect of ESI-09. Notably, administration of ESI-09 does not affect baseline pain sensitivity. ESI-09 is orally active, and its beneficial effect is maintained for at least 24 h after a single dose. These properties make ESI-09 an attractive candidate for clinical translation.

Epac1 acts as a GEF for Rap1 (9, 10), and, in line with a key role of Epac1 in pain signaling, Rap1-GTP levels were increased in DRG of WT mice with CFA-induced mechanical hyperalgesia, whereas we did not detect any change in Rap1-GTP in DRG of Epac1−/− mice. Thus, although multiple signaling pathways can activate Rap1, Epac1 is required for Rap1 activation in the DRG in the context of inflammatory pain.

Fig. 4. Effects of phospho-mimicking Epac1 mutant on Epac1-to-Rap signaling. (A) FRET analyses of 8-pCPT-AM-induced conformational changes of Epac1 in cells. HEK293 cells were transfected with either WT ECFP–Epac1–citrine (WT) or ECFP–Epac1–S108E–citrine (S108E) FRET probes. Cells were analyzed by flow cytometry after treatment with 30 μM 8-pCPT-AM. Representative panels show FRET ratios (405/530) and the percent of YFP-positive cells with FRET signal. Bar graph shows percent FRET signal decrease in response to 8-pCPT-AM treatment compared with vehicle-treated cells for three experiments performed in triplicate. ****P < 0.0001 (two-way ANOVA). (B) In vitro Epac1 GEF activity using a Rap1b-bodipy–GDP (Rap1b-bGDP) fluorescence assay. A concentration of 0.2 μM WT GST–Epac1 (WT), the phospho-deficient mutant GST–Epac1–S108A (S108A), or the phosphomimic mutant GST–Epac1–S108E (S108E) was incubated with 0.5 μM fluorescent Rap1b–bGDP and 50 μM GDP in the presence or absence of 25 μM cAMP added at 0 min. Decrease in fluorescence intensity was recorded as a measure of GEF activity. Bar graph fluorescence signal at 12 min after cAMP addition. (C) Effect of addition of GRK2 (0.2 μM) and ATP (100 μM) on in vitro Epac1 GEF activity as assessed in B. No significant differences were observed between WT GST–Epac1 and the two mutants or after addition of GRK2 (n = 3).

Fig. 5. Impaired 8-pCPT–induced PM translocation of Epac1–S108E. (A) N2A cells were transfected with WT YFP–Epac1 (WT) or the phospho-mimic mutant YFP–Epac1–S108E, and stimulated with 8-pCPT-AM for 10 min. (Scale bars, 25 μm.) *P < 0.05. (B) N2A cells transfected with WT YFP–Epac1 and siRNA GRK2 or scrambled siRNA (scr) and stimulated with 8-pCPT-AM as in A. Shown are representative images. Bar graph represents mean percentage of cells with Epac1 accumulation in the PM in response to 8-pCPT as determined in three independent experiments each including >50 cells per condition. (Scale bars, 25 μm.) *P < 0.05. (C) Rap1 activation in N2A cells transfected with WT Epac1 (ICUE1-WT) or Epac1–S108E (ICUE1-S108E) (Left) or with PM-tagged WT Epac1 (ICUE1-PM-WT) or PM-tagged Epac1–S108E (ICUE1-PM-S108E) (Right), and stimulated with 8-pCPT-AM for 10 min.
findings collectively support a model in which GRK2-mediated phosphorylation of Epac1 prevents Rap1 activation and thereby reduces inflammatory mechanical hyperalgesia.

Epac1-to-Rap1 signaling is a multistep process involving cAMP-induced liberation of Epac1 from a closed, autoinhibitory state of cAMP-driven CDC25-HD domain and GEF activity (8, 11, 24, 33, 34). Our FRET analysis revealed that in cells, the Epac1 mutant that mimics phosphorylation by GRK2 (Epac1–S108E) undergoes normal agonist-induced conformational changes. In addition, in vitro experiments showed that the ability of WT Epac1 in the presence or absence of GRK2 and of phospho-mimic Epac1 to function as a Rap1–GEF did not differ. Nevertheless, phosphorylation by GRK2 markedly reduced Epac1-mediated Rap1 activation in cells. We propose that the GRK2-mediated inhibition of Rap1 activation results from impaired agonist-induced PM accumulation of phosphorylated Epac1. This model is supported by the reduced 8-pCPT–induced PM accumulation of the phospho-mimic mutant of Epac1, whereas reducing cellular GRK2 levels increases PM accumulation of WT Epac1. Moreover, signaling of the phospho-mimic mutant of Epac1 to Rap1 normalized when it was targeted to the PM by addition of a CAAX motif. PM phosphatidic acid (PA) functions as the anchor for activated Epac1 in response to cAMP, and this binding requires Arg-82 in the DEP domain of Epac (11, 35, 36). PA-dependent PM anchoring of DEP domain-containing proteins also requires penetration of hydrophobic amino acids into the acyl layer of the PM (37). Given our results and the amino acid sequence of the region surrounding Ser-108 in Epac1, it is conceivable that the negative charge added by phosphorylation of Ser-108 reduces its hydrophobicity and introduces negative charges, thereby inhibiting PM accumulation of phosphorylated Epac1.

It remains to be determined which downstream signaling pathways are responsible for the increased mechanical sensitivity of pain-sensing neurons downstream of Epac1-to-Rap1 signaling. A recent study has shown that Epac1 activation increases mechanoreceptors mediated by the mechanosensitive channel Piezo2 (7). We show that inhibition of Epac1 signaling by overexpression of GRK2 prevents Epac-mediated sensitization of Piezo2-mediated mechanoreceptors. Moreover, decreasing DRG Piezo2 levels in vivo by using asODN treatment protects against neuropathic pain (7) and, as shown here, inhibited the late phase of CFA-induced mechanical hypersensitivity. Consistent with a previous study (38), however, we did not detect a role for Piezo2 in CFA-induced mechanical hyperalgesia as measured 24 h after CFA administration. These findings indicate that the early (<24 h) and late phases of CFA-induced mechanical hyperalgesia are mediated via different mechanisms. Indeed, a recent study showed that only the early phase of CFA-induced hyperalgesia (<5 h) was reduced by the PKA inhibitor PKI, whereas inhibition of the Epac1 target PKCe reduced CFA-induced hyperalgesia during the later phase (39). In addition, there is evidence that CFA-induced inflammation leads to a shift in cAMP signaling from a PKA to a PKCε–mediated pathway (40). On the basis of these earlier findings, we propose that Epac1-mediated sensitization of neuronal Piezo2 contributes to the later phase of CFA-induced hyperalgesia, whereas PKA-mediated Piezo2-independent pathways are operative early after CFA injection. Epac1 signaling could contribute to pain via Piezo2-independent pathways as well. For example, Epac activation leads to closure of potassium channels in pancreatic β cells (41), whereas many antiinflammatory drugs work by opening potassium channels in sensory neurons (42). In addition, Piezo2 is expressed in non-neuronal cells, including astrocytes and endothelial cells (43, 44), and we cannot exclude that Piezo2 asODN treatment inhibits CFA-induced hyperalgesia via reducing Piezo2 levels in these cells.

In conclusion, we propose that Epac1 plays a critical role in inflammatory pain via a mechanism involving PM Epac1-to-Rap1 signaling and sensitization of Piezo2-mediated mechanoreceptors. We also propose that constitutive GRK2-mediated phosphorylation of Epac1 on Ser-108 represents an essential control mechanism for cAMP–Epac1–dependent functions including mechanical hyperalgesia. Epac1 is known to contribute to multiple processes within and outside the nervous system, including neuronal excitability, long-term potentiation, axon guidance, muscle excitation and contraction, cell migration and adhesion, learning, regulation of inflammation, and energy homeostasis (15, 45–47). It is likely that the GRK2-mediated phosphorylation of Epac1 leading to reduced Epac1-to-Rap1 signaling that we uncovered here regulates these processes as well.

Materials and Methods

We used Epac1−/− mice (17, 48) and their WT littermates in a C57BL/6 background at an age of 12–14 wk. All procedures were performed in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals (49) and were approved by the Institutional Animal Care and Use Committee of the University of Texas MD Anderson Cancer Center. Mechanical hyperalgesia was measured by using von Frey hairs, and heat withdrawal latency times were determined by using the Hargreaves (10°C Life Science). The 8-pCPT and 8-pCPT–acetoxymethyl ester (AM) (Axxora) were dissolved in DMSO. ESI-09 was dissolved in ethanol (5 mg/ml) followed by dilution in corn oil (1:1) and speed vacuum to remove ethanol. GTP-bound Rap1 was pulled down by using Ral-GDS beads (18), and Rap1 was quantified by Western blotting. Currents were recorded as described (7) by using Axopatch 200B and Multiclamp 700 amplifiers (Axon Instruments, Molecular Devices) from HEK293 cells. In vitro Epac1 GEF activity was measured by using a similar protocol as described (28). Cells were imaged by using a DeltaVision Deconvolution Microscope (Applied Precision) or a SPE Leica Confocal Microscope (Leica Microsystems) at 37 °C. Data are expressed as mean ± SEM and were analyzed by using two-tailed Student’s t test or one- or two-way ANOVA.
ACKNOWLEDGMENTS. We thank Drs. F. Zwartkruis and J. Bos (University Medical Center Utrecht) and Dr. J. Zang (Johns Hopkins University School of Medicine) for sharing Epac1 constructs; Dr. H. L. D. M. Willemens (University Medical Center Utrecht) for providing GRK2 constructs; Mr. B. Igwe for contributing to subcloning; Dr. J. Zhong (Baylor College of Medicine) for help with image capture; and Dr. John Wood (University College London) for facilitating the electrophysiology experiments. This work was supported by National Institutes of Health Grants R01 NS073939, R01 NS074999, R01 GM066170, and R01GM106218 and High-End Instrumentation Program 15100D012304-01; Cancer Prevention Research Institute of Texas Center for Cancer and Endowment Development Grant R21CA130397 (a University of Texas System Science and Technology Acquisition and Retention grant); Ministerio de Economia y Competitividad Grant SAF2014-55511-R; Comunidad de Madrid Grant S2010/BMD-2323 (Inter-Disciplinary Research Network); Ministerio Sanidad y Consumo-Instituto Carlos III Cardiovascular Network Grant RD12/0402/012; a European Foundation for the Study of Diabetes-Novo Nordisk grant; and by Universidad Autónoma de Madrid–Banco de Santander.